IL-4-producing CD8+ T cells may be an immunological hallmark of chronic GVHD

Bone Marrow Transplantation

Volumn 36, Issue 7, 2005, Pages 639-647

  Nakamura, K ^a   Amakawa, R ^a   Takebayashi, M ^a   Son, Y ^a   Miyaji, M ^a   Tajima, K ^a   Nakai, K ^a   Ito, T ^a   Matsumoto, N ^a   Zen, K ^a   Kishimoto, Y ^a   Fukuhara, S ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Chronic GVHD; Cytokines; HSCT; IL 4 producing CD8+ T cells

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; GAMMA INTERFERON; INTERLEUKIN 4; METHOTREXATE; PREDNISOLONE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; IMMUNOLOGICAL PARAMETERS; LYMPHOCYTE COUNT; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; T LYMPHOCYTE;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; CYTOKINES; FEMALE; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERON TYPE II; INTERLEUKIN-4; MALE; MIDDLE AGED; RECURRENCE; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 30944446190     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705107     Document Type: Article

References (35)

1. Storb R, Thomas ED. Graft-versus-host disease in dog and man: The Seattle experience. Immunol Rev 1985; 88: 215-238.
2. Roy J, McGlave PB, Filipovich AH et al. Acute graft-versus-host disease following unrelated donor marrow transplantation: Failure of conventional therapy. Bone Marrow Transplant 1992; 10: 77-82.
3. Atkinson K, Horowitz MM, Gale RP et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75: 2459-2464.
4. Ochs LA, Miller WJ, Filipovich AH et al. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation. Bone Marrow Transplant 1994; 13: 455-460.
5. Sutherland HJ, Fyles GM, Adams G et al. Quality of life following bone marrow transplantation: A comparison of patient reports with population norms. Bone Marrow Transplant 1997; 19: 1129-1136.
6. Syrjala KL, Chapko MK, Vitaliano PP et al. Recovery after allogeneic marrow transplantation: A comparison of patient reports with population norms. Bone Marrow Transplant 1993; 11: 319-327.
7. Duell T, van Lint MT, Ljungman P et al. Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation. Ann Intern Med 1997; 126: 184-192.
8. Sad S, Marcotte R, Mosmann TR. Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8 + T cells secreting Th1 or Th2 cytokines. Immunity 1995; 2: 271-279.
9. Croft M, Carter L, Swain SL, Dutton RW. Generation of polarized antigen-specific CD8 effector populations: Reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 1994; 180: 1715-1728.
10. Kayaba H, Hirokawa M, Watanabe A et al. Serum markers of graft-versus-host disease after bone marrow transplantation. J Allergy Clin Immunol 2000; 106: S40-S44.
11. Kami M, Matsumura T, Tanaka Y et al. Serum levels of soluble interleukin-2 receptor after bone marrow transplantation: A true marker of acute graft-versus-host disease. Leuk Lymphoma 2000; 38: 533-540.
12. Abdallah AN, Boiron JM, Attia Y et al. Plasma cytokines in graft vs host disease and complications following bone marrow transplantation. Hematol Cell Ther 1997; 39: 27-32.
13. Miyamoto T, Akashi K, Hayashi S et al. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplant 1996; 17: 185-190.
14. Imamura M, Hashino S, Kobayashi H et al. Serum cytokine levels in bone marrow transplantation: Synergistic interaction of interleulcin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease. Bone Marrow Transplant 1994; 13: 745-751.
15. Nakamura H, Komatsu K, Ayaki M et al. Serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFN-gamma in patients with acute graft-versus-host disease after allogeneic bone marrow transplantation. J Allergy Clin Immunol 2000; 106: S45-50.
16. Niederwieser D, Herold M, Woloszczuk W et al. Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation 1990; 50: 620-625.
17. Min CK, Lee VVY, Min DJ et al. The kinetics of circulating cytokines including IL-6, TNF-alpha, IL-8 and IL-10 following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 935-940.
18. Symington FW, Symington BE, Liu PY et al. The relationship of serum IL-6 levels to acute graft-versus-host disease and hepatorenal disease after human bone marrow transplantation. Transplantation 1992; 54: 457-462.
19. Ferrara JL. Cytokine dysregulation as a mechanism of graft versus host disease. Curr Opin Immunol 1993; 5: 794-799.
20. Fallen PR, McGreavey L, Madrigal JA et al. Factors affecting reconstitution of the T cell compartment in allogeneic haematopoietic cell transplant recipients. Bone Marrow Transplant 2003; 32: 1001-1014.
21. Tanaka J, Imamura M, Kasai M et al. The important balance between cytokines derived from type 1 and type 2 helper T cells in the control of graft-versus-host disease. Bone Marrow Transplant 1997; 19: 571-576.
22. Allen RD, Staley TA, Sidman CL. Differential cytokine expression in acute and chronic graft-versus-host-disease. Eur J Immunol 1993; 23: 333-337.
23. Foss FM, Gorgun G, Miller KB. Extracorporeal photopheresis in chronic graft-versus-host disease. Bone Marrow Transplant 2002; 29: 719-725.
24. Korholz D, Kunst D, Hempel L et al. Decreased interleukin 10 and increased interferon-gamma production in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 691-695.
25. Barak V, Levi-Schaffer F, Nisman B, Nagler A. Cytokine dysregulation in chronic graft-versus-host Disease. Leak Lymphoma 1995; 17: 169-173.
26. Liem LM, van Houwelingen HC, Goulmy E. Serum cytokine levels after HLA-identical bone marrow transplantation. Transplantation 1998; 66: 863-871.
27. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
28. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
29. Hamann D, Baars PA, Rep MH et al. Phenotypic and functional separation of memory and effector human CD8 + T cells. J Exp Med 1997; 186: 1407-1418.
30. Milica V-S, Beejal V, Patricia G-S et al. Human Tc1 and Tc2/Tc0 CD8 T-cell clones display distinct cell surface and functional phenotypes. Blood 2000; 95: 231-240.
31. Le Gros G, Erard F. Non-cytotoxic, IL-4, IL-5, IL-10 producing CD8+ T cells: Their activation and effector functions. Curr Opin Immunol 1994; 6: 453-457.
32. Cronin Jr DC, Stack R, Fitch FW. IL-4-producing CD8 + T cell clones can provide B cell help. J Immunol 1995; 154: 118-127.
33. De Wit D, van Mechelen M, Zanin C et al. Preferential activation of Th2 cells in chronic graft-versus-host reaction. J Immunol 1993; 150: 361-366.
34. Garlisi CG, Pennline KJ, Smith SR et al. Cytokine gene expression in mice undergoing chronic graft-versus-host disease. Mol Immunol 1993; 30: 669-677.
35. Umland SP, Razac S, Nahrebne DK, Seymour BW. Effects of in vivo administration of interferon (IFN)-gamma, anti-IFN-gamma, or anti-interleukin-4 monoclonal antibodies in chronic autoimmune graft-versus-host disease. Clin Immunol Immunopathol 1992; 63: 66-73.